Adult Cohort Group 1 for Pneumococcal Vaccines (IVT PCV-25 Trial)

"According to the clinical trial sponsor, Inventprise Inc., the primary metric for evaluating safety is Adult Safety: unsolicited adverse events. Further measurements will be taken 6 months after vaccination (Day 448), such as Adult Immunogenicity: GMFR OPA GMTs and Infant Immunogenicity: OPA titers along with Serotype-specific IgG GMCs as an indication of adult immunogenicity."

"This medical study has a maximum capacity of 520 participants, who must fit into one of three categories: adults aged 18 to 40 years old; children from 24 months to 59 months; or infants 8 weeks through 11 weeks. Furthermore, applicants cannot be immunocompromised and must adhere to Canadian national COVID-19 vaccination regulations (where applicable). All patients that aren't surgically sterile will also need negative pregnancy tests at screening and prior to the vaccine's administration. Finally, all subjects are required to fully comprehend their obligations as part of this trial and provide voluntary written consent in order for admission."

"For participation in this medical trial, patients must be between 8 Weeks and 40 years old. There are separate research projects for minors below 18 and those over 65."

"Affirmative. Documentation on clinicaltrials.gov verifies that this research endeavour, which was initially advertised on September 28th 2022, is currently recruiting participants. Around 520 individuals need to be recruited from 1 site for the study to commence."

"Affirmative, the details posted on clinicaltrials.gov demonstrate that this medical trial is actively enrolling participants. Initially published on September 28th 2022, it was last modified on November 6th 2022 and requires 520 individuals to be recruited from a single site."